"Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression" READ UPDATE ON THE SELECT-MDS-1 TRIAL Anne Cancer Survivor

Tamibarotene (formerly SY-1425) is a first-in-class selective retinoic acid receptor alpha (RARα) agonist that is currently in a Phase 2 clinical trial in a genomically defined subset of AML patients, including those with relapsed or refractory AML.

Feb 28, 2025 · Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

Syros’ mission was to develop new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros had developed tamibarotene, an oral selective RARα agonist, in frontline patients with higher-risk ...

Our gene control platform has served as the foundation for our clinical stage pipeline and has been used to identify targets and biomarkers for drug development with the aim of providing a profound benefit for patients with diseases that have …

Oct 31, 2024 · Syros did not recognize revenue in the third quarter of 2024, as compared to $3.8 million for the third quarter of 2023. The decrease reflects the termination of Syros’ collaboration agreement with Pfizer.

Jan 8, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

Feb 28, 2025 · Syros is driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and we aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies.

May 14, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.

Dec 5, 2020 · Syros is advancing a robust clinical-stage pipeline, including SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and ...